TRCT
CGEM icon

Tower Research Capital (TRC)’s Cullinan Oncology CGEM Stock Holding History

Tower Research Capital (TRC)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.1K Sell
3,191
-941
-23% -$14K ﹤0.01% 2618
2026
Q1 		$58.7K Buy
4,132
+3,226
+356% +$41.5K ﹤0.01% 2601
2025
Q4 		$9.38K Sell
906
-6,661
-88% -$60.1K ﹤0.01% 3902
2025
Q3 		$44.9K Sell
7,567
-615
-8% -$4.5K ﹤0.01% 2614
2025
Q2 		$61.6K Buy
8,182
+2,523
+45% +$20.3K ﹤0.01% 2791
2025
Q1 		$42.8K Sell
5,659
-3,141
-36% -$30.1K ﹤0.01% 2329
2024
Q4 		$107K Buy
8,800
+7,079
+411% +$102K ﹤0.01% 2114
2024
Q3 		$28.8K Sell
1,721
-2,303
-57% -$40.9K ﹤0.01% 3025
2024
Q2 		$70.2K Buy
4,024
+3,699
+1,138% +$78.8K ﹤0.01% 2843
2024
Q1 		$5.54K Sell
325
-9,909
-97% -$153K ﹤0.01% 4529
2023
Q4 		$104K Sell
10,234
-5,156
-34% -$45.7K ﹤0.01% 2619
2023
Q3 		$139K Buy
15,390
+12,330
+403% +$128K ﹤0.01% 1723
2023
Q2 		$32.9K Buy
3,060
+858
+39% +$9.11K ﹤0.01% 2942
2023
Q1 		$23K Buy
2,202
+1,002
+84% +$11K ﹤0.01% 3275
2022
Q4 		$12K Sell
1,200
-494
-29% -$6K ﹤0.01% 3690
2022
Q3 		$22K Buy
1,694
+222
+15% +$2.99K ﹤0.01% 3853
2022
Q2 		$19K Sell
1,472
-3,842
-72% -$43.6K ﹤0.01% 3835
2022
Q1 		$55K Sell
5,314
-532
-9% -$7.19K ﹤0.01% 2652
2021
Q4 		$90K Buy
5,846
+5,107
+691% +$102K ﹤0.01% 2295
2021
Q3 		$17K Sell
739
-26
-3% -$695 ﹤0.01% 3853
2021
Q2 		$20K Sell
765
-55
-7% -$1.69K ﹤0.01% 3873
2021
Q1 		$34K Buy
+820
New +$33.3K ﹤0.01% 3442

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Tower Research Capital (TRC)'s CGEM Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Cullinan Oncology (CGEM) stake by 23% in Q2 2026, selling an estimated $14K and leaving 3,191 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Tower Research Capital (TRC) first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $139K in Q3 2023. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Tower Research Capital (TRC) held 3,191 shares of Cullinan Oncology worth $58.1K as of Q2 2026.
  • Tower Research Capital (TRC) sold 941 Cullinan Oncology shares in Q2 2026, an estimated $14K.
  • Cullinan Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2618 holding.
  • Tower Research Capital (TRC) first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Cullinan Oncology position peaked at $139K in Q3 2023.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.